Stocks · News reference

Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $415

Sep 10, 2026, 1:08 PMBenzinga Newsdesk

Barclays analyst Etzer Darout maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $407 to $415.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Sep 10, 2026, 1:08 PM
Checked: Sep 10, 2026, 1:08 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 1, 2026, 8:57 AMNamrata Sen
Trump Expands Drug Pricing Deals With 9 Pharma Companies, Bringing Total to 26 — RFK Jr. Details 'Very, Very Emotional' Conversations With President
Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from the President to deliver.
ALC BBIO LLY NVO ONC
BenzingaAug 31, 2026, 7:44 PMBenzinga Newsdesk
Trump Administration Reaches New Drug Pricing Agreement With Nine Pharma Firms
BBIO ONC SPY TEVA
BenzingaAug 31, 2026, 7:07 PMBenzinga Newsdesk
BeOne Medicines Inks Voluntary Agreement With U.S. Government To Expand Access To Cancer Drugs For American Patients
ONC